Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) EBIT Margin (2016 - 2025)

CorMedix (CRMD) has disclosed EBIT Margin for 14 consecutive years, with 46.27% as the latest value for Q4 2025.

  • Quarterly EBIT Margin fell 14635.0% to 46.27% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 10.11% through Dec 2025, up 1944.0% year-over-year, with the annual reading at 10.11% for FY2025, 1944.0% up from the prior year.
  • EBIT Margin hit 46.27% in Q4 2025 for CorMedix, down from 49.24% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 201753.24% in Q2 2023 to a low of 102126.07% in Q3 2022.
  • Historically, EBIT Margin has averaged 10406.98% across 5 years, with a median of 46.27% in 2025.
  • Biggest five-year swings in EBIT Margin: surged 24052633bps in 2023 and later plummeted -20365132bps in 2024.
  • Year by year, EBIT Margin stood at 13794.92% in 2021, then crashed by -105bps to 28244.66% in 2022, then skyrocketed by 383bps to 79823.71% in 2023, then plummeted by -100bps to 100.08% in 2024, then plummeted by -146bps to 46.27% in 2025.
  • Business Quant data shows EBIT Margin for CRMD at 46.27% in Q4 2025, 49.24% in Q3 2025, and 49.18% in Q2 2025.